Lisdexamfetamine
- Generic Name
- Lisdexamfetamine
- Brand Names
- Vyvanse
- Drug Type
- Small Molecule
- Chemical Formula
- C15H25N3O
- CAS Number
- 608137-32-2
- Unique Ingredient Identifier
- H645GUL8KJ
- Background
Lisdexamfetamine is a prodrug of dextroamphetamine, a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved by Health Canada in February 2009. Lisde...
- Indication
Lisdexamfetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients six years and older. It is also indicated to treat moderate to severe binge eating disorder (BED) in adults. It is approved for use in the US and Canada.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Moderate Binge Eating Disorder (BED), Severe Binge Eating Disorder (BED)
- Associated Therapies
- -
Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Medical University of Lodz
- Target Recruit Count
- 150
- Registration Number
- NCT05957055
- Locations
- 🇵🇱
Pediatric Center of the Central Clinical Hospital of the Medical University of Lodz, Łódź, Łódzkie, Poland
Vyvanse in Children Aged 6 to 12 Years
- Conditions
- Interventions
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 40
- Registration Number
- NCT05416125
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
The Day-time Response Variation of (Lis)Dexamphetamine
- Conditions
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 16
- Registration Number
- NCT04946461
- Locations
- 🇳🇱
ADHDcentraal, Amsterdam, Noord Holland, Netherlands
The Use of Lisdexamfetamine for Children Aged 7-13 With Attention Deficit Disorders
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2021-08-11
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 413
- Registration Number
- NCT04727476
- Locations
- 🇩🇰
Department of Child and Adolescent Psychiatry, Aarhus University Hospital, Aarhus, Region Midt, Denmark
Effects of LDX on Cognitive Processes and Appetite
- Conditions
- Interventions
- First Posted Date
- 2019-12-02
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 22
- Registration Number
- NCT04181957
- Locations
- 🇬🇧
University of Birmingham, Birmingham, United Kingdom
Real World Evidence of the Efficacy and Safety of FOQUEST
- Conditions
- Interventions
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Purdue Pharma, Canada
- Target Recruit Count
- 257
- Registration Number
- NCT04152629
- Locations
- 🇨🇦
Health Sciences North, Sudbury, Ontario, Canada
🇨🇦Matheson Centre for Mental Health Research & Education, University of Calgary, Calgary, Alberta, Canada
🇨🇦Alpha recherche clinique, Québec, Quebec, Canada
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 430000
- Registration Number
- NCT04132557
- Locations
- 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Yale University
- Target Recruit Count
- 80
- Registration Number
- NCT03926052
- Locations
- 🇺🇸
Yale Department of Psychiatry, New Haven, Connecticut, United States
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Yale University
- Target Recruit Count
- 141
- Registration Number
- NCT03924193
- Locations
- 🇺🇸
Yale Department of Psychiatry, New Haven, Connecticut, United States
Bariatric Surgery and Pharmacokinetics of Lisdexamphetamine
- Conditions
- First Posted Date
- 2018-04-13
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 12
- Registration Number
- NCT03497169
- Locations
- 🇳🇴
St. Olavs University Hospital, Trondheim, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.